Patent · US Active

Hornfly vaccine methods

US11780894B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

TNG Pharmaceuticals, Inc. · US

Inventors

Kent R. Van Kampen · Birmingham, US
Serge Martinod · Groton, US

Key dates

Filing date	Dec 13, 2018
Grant date	Oct 10, 2023
Priority date	—
Expiry date	Mar 21, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.